A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Conditions: Cohort 1a and 1b: Glioma; Cohort 1a and 1b: Glioblastoma Multiforme; Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas); Cohort 3a and 3b: Chondrosarcoma; Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma; Cohort 5a: Other Solid Tumors With IDH1 Mutations Interventions: Drug: FT-2102; Drug: Azacitidine; Biological: Nivolumab; Drug: Gemcitabine and Cisplatin Sponsor: Forma Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bile | Bile Duct Cancer | Brain Tumor | Cancer & Oncology | Carcinoma | Cholangiocarcinoma | Chondrosarcoma | Glioma | Hepatocellular Carcinoma | Liver Cancer | Study